Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified breast cancer~* Large (≥ 3 cm) breast cancer~* IIb-IIIa stage~* ECOG (Eastern Cooperative Oncology Group) status: 0-1-2~* Adequate bone marrow reserve: (Haemoglobin ≥ 12g/l, Absolute Neutrophil Count (ANC) ≥ 2.0x 10\^9, Platelets ≥100 000)~* Laboratory results:~* Bilirubin ≤ Upper Limit Normal (ULN)~* Serum Glutamate Pyruvate Transaminase (SGPT) ≤ 2.5 ULN, Serum Glutamate Oxaloacetate Transaminase (SGOT) ≤ 2.5 ULN,~* Alk.phosph. ≤ 5.0 ULN,~* Creatinin ≤ ULN, if borderline calculated at ≤ 60ml/min~* Normal cardiac function (the result of Left Ventricular Ejection Function (LVEF) must be above the lower limit of normal for the institution)~* Negative pregnancy test~* Hormonal receptor status assessed~Exclusion Criteria:~* Pregnancy or lactation~* SGOT and/or SGPT \> 1.5 upper limit normal, associated with Alk.phosph \> 2.5 ULN~* Serious medical condition including but not limited to:~* Uncontrolled hypertension~* Active ulcus pepticum~* Non-stable diabetes mellitus~* Other contraindication of steroid treatment~* Myocardial infarction within the last 6 months prior study entry~* Significant neurologic/psychiatric disorders~* Active infection~* Peripheral neuropathy grade ≥ 2~* Unstable angina~* Severe arrhythmia~* Participation in other clinical trial~* Prior surgery, chemotherapy, hormonotherapy for breast cancer~* Past or current history of neoplasm other than breast cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 7 years~* History of hypersensitivity to the investigational products or to drugs with similar chemical structures~* Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol~* Treatment with any investigational product in the last 1 month before study entry.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).